ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2814

Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE

Jennie Hamilton1, Qi Wu2, PingAr Yang3, Bao Luo4, Shanrun Liu5, Jun Li6, Ignacio Sanz7, W. Winn Chatham8, Hui-Chen Hsu2 and John D. Mountz9, 1Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, 6Medicine, University of Alabama at Birmingham, Birmingham, AL, 7Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, 8Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9University of Alabama at Birmingham, Department of Medicine, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: African-Americans, autoantibodies, Interferons and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Plasmacytoid dendritic cells are considered the main source of pathogenic IFN in SLE. However, recent work found that elevated serum type I IFN protein was not accompanied by increased type I IFN in circulating pDCs, suggesting the importance of other cellular sources of type I IFN in some patients. Developing transitional B cells are important targets of type I IFN in SLE, and were recently shown to produce IFNα. IFNβ expression has not been investigated in SLE B cells; in mice, however it has been identified as a prerequisite for efficient TLR stimulation, suggesting that autocrine stimulation of developing B cells with high-affinity IFNβ may be a prerequisite for subsequent immune-competence to respond to TLR challenges.

Methods: Peripheral blood mononuclear cells (PBMCs) from 34 SLE patients and 9 healthy controls were recruited; all SLE patients met the ACR 1997 revised criteria for SLE. Comprehensive clinical data was recorded for each SLE subjectin a double-blind fashion. Intracellular analysis of endogenous IFNβ was carried out using validated reagents on FACS isolated B cells.

Results: There was a significant increase in endogenous IFNβ in transitional (p = 0.002), naive (p = 0.004) and memory (p = 0.031) B cell subpopulations of SLE patients compared to healthy controls. Endogenous IFN-β in B cells was significantly higher than endogenous IFN-β in CD4 T cells, with levels equivalent to that seen in pDCs. Endogenous IFNβ was highly correlated with clinical disease including renal disease (p = 0.0072) and autoantibodies including anti-dsDNA (p = 0.036), anti-Sm (p = 0.011) and anti-SSA (p=0.04). Notably, T1/T2 B cell IFNβ expression was significantly increased in African-American patients (p=0.011) with more severe disease manifestations. T1/T2 IFNβ expression was also significantly correlated with the percent of 9G4+ autoreactive B cells (p = 0.0001) and CD19loCD38hiCD27+ plasma cell formation (p = 0.031). Upregulation of CD69 after TLR7 stimulation with CL264 was highly dependent upon B cell endogenous secretion IFNβ and could be significantly inhibited in the presence of anti-IFNβ antibody. The specific requirement for IFNβ was demonstrated by the lack of additional inhibition in the presence of anti-IFNaR neutralizing antibody, which blocks signaling from all type I IFNs. In vitro survival of purified B cells was also dependent on IFNβ after TLR7 stimulation and was significantly decreased with blockade of IFNβ.

Conclusion: Intracellular IFNβ production by early-stage transitional B cells is a novel and important B cell intrinsic factor that regulates B cell survival and sensitivity to TLR7 stimulation. B cell endogenous IFNβ may be an essential factor for their development into autoantibody producing B cells. The present work suggests a need for future human lupus studies into type I IFN dysregulation that pioneer beyond the view of pDC produced IFNα. These results also provide a mechanistic basis for development of more effective therapies to dampen the type I IFN cascade by specifically targeting the high-affinity IFNβ or the enhanceosome components that promote its induction in a subgroup of lupus patients.


Disclosure: J. Hamilton, None; Q. Wu, None; P. Yang, None; B. Luo, None; S. Liu, None; J. Li, None; I. Sanz, None; W. W. Chatham, None; H. C. Hsu, None; J. D. Mountz, None.

To cite this abstract in AMA style:

Hamilton J, Wu Q, Yang P, Luo B, Liu S, Li J, Sanz I, Chatham WW, Hsu HC, Mountz JD. Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/interferon-%ce%b2-production-by-b-cells-promotes-b-cell-survival-and-is-strongly-associated-with-active-disease-in-african-americans-with-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interferon-%ce%b2-production-by-b-cells-promotes-b-cell-survival-and-is-strongly-associated-with-active-disease-in-african-americans-with-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology